A new generation of proprietary aptamers for more effective diagnosis and treatment

Find out more


Aptitude is hiring! See current openings.

Aptitude demonstrated the in vivo efficacy of two aptamer therapeutic programs

Aptitude has received 5 million dollars in non-dilutive funding

Aptitude started collaboration with a global leader in clinical diagnostics

Aptitude unlocks the potential of aptamers to overcome the fundamental limitations of antibodies

Imagine a synthetic antibody that:

is highly stable, resistant to denaturing, and works with diverse platforms, from mainstream assays to cutting-edge electrochemical sensors

binds with high affinity and specificity to intractable targets, and discriminates targets that differ by only a single functional group

accommodates various functional modifications, and seamlessly integrates with powerful qPCR and next-gen sequencing detection

Imagine a company who can turn that dream into reality.

Welcome to the reality of Aptitude.


our team

Find out who is behind the Aptitude technology